Healthcare / Medical DistributionThailand
$0.13
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $113.6M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$520M
P/E
13.0x
↓EV/EBITDA
6.7x
↓ROE
7.6%
↑Gross Margin
35.0%
↓Debt/Equity
0.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.4%
FCF CAGR
-18.2%
FCF margin
8.7%
FCF / Net income
2.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.31B · net income $44.6M · FCF $113.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.31B | $1.31B | $1.34B | $1.31B | $1.49B |
| Net Income | $44.6M | $44.6M | $19.7M | $13.4M | $53.0M |
| EBITDA | $119.5M | $119.5M | $108.6M | $91.2M | $131.4M |
| EPS | — | — | 0.00 | 0.00 | 0.01 |
| Gross Margin | 35.0% | 35.0% | 33.4% | 33.6% | 33.2% |
| Operating Margin | 5.4% | 5.4% | 3.3% | 3.4% | 5.2% |
| Net Margin | 3.4% | 3.4% | 1.5% | 1.0% | 3.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.52 | 0.52 | 0.69 | 0.89 | 1.13 |
| Current Ratio | 1.67 | 1.67 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $113.6M | $113.6M | $152.9M | $-863000.00 | $207.4M |
| Returns | |||||
| ROE | 7.6% | 7.6% | 3.6% | 2.6% | 10.5% |
| Valuation | |||||
| P/E | 13.00 | 13.00 | 53.06 | 46.62 | 24.82 |
| EV/EBITDA | 6.68 | 6.68 | 12.31 | 11.65 | 13.32 |
| P/B | 0.89 | 0.89 | 1.91 | 1.21 | 2.61 |
| Growth & Yield | |||||
| Revenue Growth | -2.6% | -2.6% | 2.3% | -12.2% | — |
| EPS Growth | — | — | 44.1% | -74.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.00 → n/d
Residual
-23.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.